IL-12 Initiates Tumor Rejection Via Lymphoid Tissue-inducer Cells Bearing the Natural Cytotoxicity Receptor NKp46

Overview

Journal Nat Immunol

Date 2010 Oct 12

PMID 20935648

Citations 119

Authors

Maya Eisenring

Johannes Vom Berg

Glen Kristiansen

Elisabeth Saller

Burkhard Becher

Affiliations

Soon will be listed here.

Abstract

The potent tumoricidal activity of interleukin 12 (IL-12) is thought to be mediated by the activation and polarization of natural killer (NK) cells and T helper type 1 (T(H)1) cells, respectively. By systematic analysis of the IL-12-induced immune response to subcutaneous melanoma (B16), we found that tumor suppression was mediated independently of T lymphocytes or NK cells. IL-12 initiated local antitumor immunity by stimulating a subset of NKp46(+) lymphoid tissue-inducer (LTi) cells dependent on the transcription factor RORγt. The presence of these NKp46(+) LTi cells induced upregulation of adhesion molecules in the tumor vasculature and resulted in more leukocyte invasion. Thus, this innate cell type is responsive to IL-12 and is a powerful mediator of tumor suppression.

Citing Articles

The IL-23/Th17 pathway inhibitors in the treatment of psoriasis and the risk of skin malignancies: a review.

Krzysztofik M, Brzewski P, Kulbat A, Masajada M, Richter K, Wysocki W Postepy Dermatol Alergol. 2025; 41(6):552-559.

PMID: 39877117 PMC: 11770571. DOI: 10.5114/ada.2024.143428.

Canine Adipose-Derived Mesenchymal Stromal Cells Reduce Cell Viability and Migration of Metastatic Canine Oral Melanoma Cell Lines In Vitro.

Teng F, de Faria Lainetti P, Simao Franzoni M, Fernando Leis Filho A, Massoco Salles Gomes C, Laufer-Amorim R Vet Sci. 2024; 11(12).

PMID: 39728976 PMC: 11680336. DOI: 10.3390/vetsci11120636.

Cytokines in cancer.

Kureshi C, Dougan S Cancer Cell. 2024; 43(1):15-35.

PMID: 39672170 PMC: 11841838. DOI: 10.1016/j.ccell.2024.11.011.

Advancements in the Study of the Immune Molecule NKp46 in Immune System-related Diseases.

Qian S, Zhou Y, Jin Z, Li X, Tian Y, Chen F Clin Rev Allergy Immunol. 2024; 67(1-3):96-110.

PMID: 39612130 PMC: 11638288. DOI: 10.1007/s12016-024-09010-5.

Convergent inducers and effectors of T cell paralysis in the tumour microenvironment.

Hanahan D, Michielin O, Pittet M Nat Rev Cancer. 2024; 25(1):41-58.

PMID: 39448877 DOI: 10.1038/s41568-024-00761-z.

References

Shields J, Kourtis I, Tomei A, Roberts J, Swartz M . Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science. 2010; 328(5979):749-52. DOI: 10.1126/science.1185837. View

Trinchieri G, Sher A . Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007; 7(3):179-90. DOI: 10.1038/nri2038. View

Vosshenrich C, Ranson T, Samson S, Corcuff E, Colucci F, Rosmaraki E . Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J Immunol. 2005; 174(3):1213-21. DOI: 10.4049/jimmunol.174.3.1213. View

Del Vecchio M, Bajetta E, Canova S, Lotze M, Wesa A, Parmiani G . Interleukin-12: biological properties and clinical application. Clin Cancer Res. 2007; 13(16):4677-85. DOI: 10.1158/1078-0432.CCR-07-0776. View

Crellin N, Trifari S, Kaplan C, Cupedo T, Spits H . Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. J Exp Med. 2010; 207(2):281-90. PMC: 2822607. DOI: 10.1084/jem.20091509. View

Luci C, Reynders A, Ivanov I, Cognet C, Chiche L, Chasson L . Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat Immunol. 2008; 10(1):75-82. DOI: 10.1038/ni.1681. View

Buell J, Gross T, Woodle E . Malignancy after transplantation. Transplantation. 2005; 80(2 Suppl):S254-64. DOI: 10.1097/01.tp.0000186382.81130.ba. View

Park S, Kyin T, Bendelac A, Carnaud C . The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J Immunol. 2003; 170(3):1197-201. DOI: 10.4049/jimmunol.170.3.1197. View

Sun J, Ma A, Lanier L . Cutting edge: IL-15-independent NK cell response to mouse cytomegalovirus infection. J Immunol. 2009; 183(5):2911-4. PMC: 2745285. DOI: 10.4049/jimmunol.0901872. View

10.

Schmidt S . Fusion-proteins as biopharmaceuticals--applications and challenges. Curr Opin Drug Discov Devel. 2009; 12(2):284-95. View

11.

Buckanovich R, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K . Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med. 2007; 14(1):28-36. DOI: 10.1038/nm1699. View

12.

Daud A, DeConti R, Andrews S, Urbas P, Riker A, Sondak V . Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008; 26(36):5896-903. PMC: 2645111. DOI: 10.1200/JCO.2007.15.6794. View

13.

Eberl G, Marmon S, Sunshine M, Rennert P, Choi Y, Littman D . An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nat Immunol. 2003; 5(1):64-73. DOI: 10.1038/ni1022. View

14.

Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-46. DOI: 10.1038/nri1001. View

15.

Langowski J, Zhang X, Wu L, Mattson J, Chen T, Smith K . IL-23 promotes tumour incidence and growth. Nature. 2006; 442(7101):461-5. DOI: 10.1038/nature04808. View

16.

Schrama D, Thor Straten P, Fischer W, McLellan A, Brocker E, Reisfeld R . Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity. 2001; 14(2):111-21. DOI: 10.1016/s1074-7613(01)00094-2. View

17.

. Sciencescope. Science. 1995; 268(5217):1555. DOI: 10.1126/science.268.5217.1555. View

18.

Noguchi Y, Jungbluth A, Richards E, Old L . Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci U S A. 1996; 93(21):11798-801. PMC: 38138. DOI: 10.1073/pnas.93.21.11798. View

19.

Shankaran V, Ikeda H, Bruce A, White J, Swanson P, Old L . IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001; 410(6832):1107-11. DOI: 10.1038/35074122. View

20.

Smyth M, Thia K, Street S, Cretney E, Trapani J, Taniguchi M . Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000; 191(4):661-8. PMC: 2195840. DOI: 10.1084/jem.191.4.661. View